Nov 04, 2019 7:00am EST Can-Fite Initiates Compassionate Use Program for Namodenoson in the Treatment of Liver Cancer, Enrolls and Treats Patients
Oct 31, 2019 7:00am EDT U.S. FDA Agreed with Can-Fite’s Proposed Pivotal Phase III Trial Design to Support a New Drug Application Submission and Approval of Namodenoson in the Treatment of Liver Cancer
Oct 17, 2019 8:00am EDT Can-Fite and Gebro Pharma holding European Conference on Development & Commercialization of Phase III Drug Candidate Piclidenoson in the Treatment of Rheumatoid Arthritis
Oct 16, 2019 7:00am EDT Can-Fite BioPharma Interview to Air on Bloomberg International on the RedChip Money Report
Oct 10, 2019 7:00am EDT Can Fite Announces Publication of Namodenoson™ NASH Mechanism of Action in International Journal of Molecular Medicine
Sep 23, 2019 7:00am EDT Can-Fite Presents New Data on the Treatment of Advanced Liver Cancer with Namodenoson at the ILCA Conference
Sep 10, 2019 6:03am EDT Can-Fite Enters into Strategic Agreement with Univo Pharmaceuticals to Develop Cannabinoid-Based Pharmaceuticals and Assays
Sep 05, 2019 7:00am EDT Can-Fite to Present at H. C. Wainwright 21st Annual Global Investment Conference on September 10, 2019
Aug 29, 2019 7:00am EDT Can-Fite Reports Second Quarter 2019 Financial Results & Provides Clinical Update
